<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258527</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI375A101</org_study_id>
    <nct_id>NCT04258527</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations</brief_title>
  <official_title>A Phase 1, Open-Label, Pharmacokinetic(PK), Pharmacodynamics(PD) and Safety Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects
      with advanced malignancies with FGF/FGFR alterations.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the single-dose plasma concentration-time curve (AUC0-t) of Pemigatinib as monotherapy</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of pemigatinib as monotherapy as assessed by the frequency, duration, and severity of adverse events</measure>
    <time_frame>From screening through 30-35 days after end of treatment, up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Patients with advanced malignancies with FGF/FGFR alterations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemigatinib</intervention_name>
    <description>Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.</description>
    <arm_group_label>Patients with advanced malignancies with FGF/FGFR alterations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 18 or older.

          2. Histologically or cytologically confirmed malignancy which was considered to be
             surgically unresectable advanced, relapse or metastatic .

          3. Radiographically measurable disease per RECIST v 1.1

          4. Documentation of FGF/FGFR alteration..

          5. Documented disease progression after standard therapy ,or no standard therapy
             available.

          6. ECOG performance status of 0~1.

          7. Life expectancy â‰¥12 weeks

        Exclusion Criteria:

          1. Prior receipt of a selective FGFR inhibitor.

          2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance
             with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or
             vessels due to injury, disease, and aging, in the absence of systemic mineral
             imbalance).

          3. Currently evidence of clinically significant corneal or retinal disorder confirmed by
             ophthalmologic examination.

          4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives,
             whichever is shorter, before the first dose of study drug. Topical ketoconazole will
             be allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yujiao Jin</last_name>
    <phone>0512-69566088</phone>
    <email>yujiao.jin@innoventbio.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

